Síntesis amplia / Guía

No clasificado

Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Año 2012
Revista Chest
Enlaces DOI , PMC , Pubmed

Sin referencias

Cargando información sobre las referencias
Mostrar resumen

BACKGROUND:

The risk of stroke varies considerably across different groups of patients with atrial fibrillation (AF). Antithrombotic prophylaxis for stroke is associated with an increased risk of bleeding. We provide recommendations for antithrombotic treatment based on net clinical benefit for patients with AF at varying levels of stroke risk and in a number of common clinical scenarios.

METHODS:

We used the methods described in the Methodology for the Development of Antithrombotic Therapy and Prevention of Thrombosis Guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines article of this supplement.

RESULTS:

For patients with nonrheumatic AF, including those with paroxysmal AF, who are (1) at low risk of stroke (eg, CHADS(2) [congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischemic attack] score of 0), we suggest no therapy rather than antithrombotic therapy, and for patients choosing antithrombotic therapy, we suggest aspirin rather than oral anticoagulation or combination therapy with aspirin and clopidogrel; (2) at intermediate risk of stroke (eg, CHADS(2) score of 1), we recommend oral anticoagulation rather than no therapy, and we suggest oral anticoagulation rather than aspirin or combination therapy with aspirin and clopidogrel; and (3) at high risk of stroke (eg, CHADS(2) score of ≥ 2), we recommend oral anticoagulation rather than no therapy, aspirin, or combination therapy with aspirin and clopidogrel. Where we recommend or suggest in favor of oral anticoagulation, we suggest dabigatran 150 mg bid rather than adjusted-dose vitamin K antagonist therapy.

CONCLUSIONS:

Oral anticoagulation is the optimal choice of antithrombotic therapy for patients with AF at high risk of stroke (CHADS(2) score of ≥ 2). At lower levels of stroke risk, antithrombotic treatment decisions will require a more individualized approach.

Mostrar resumen

Revisión sistemática

No clasificado

Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis.

Año 1999
Autores Hart RG , Benavente O , McBride R , Pearce LA
Revista Annals of internal medicine
Enlaces DOI , Pubmed
Cargando información sobre las referencias
Mostrar resumen

PURPOSE:

To characterize the efficacy and safety of anticoagulants and antiplatelet agents for prevention of stroke in patients with atrial fibrillation.

DATA SOURCES:

Randomized trials identified by using the search strategy developed by the Cochrane Collaboration Stroke Review Group.

STUDY SELECTION:

All published randomized trials testing antithrombotic agents to prevent stroke in patients with atrial fibrillation.

DATA EXTRACTION:

Data on interventions, number of participants, duration of exposure and occurrence of all stroke (ischemic and hemorrhagic), major extracranial bleeding, and death were extracted independently by two investigators.

DATA SYNTHESIS:

Sixteen trials included a total of 9874 participants (mean follow-up, 1.7 years). Adjusted-dose warfarin (six trials, 2900 participants) reduced stroke by 62% (95% CI, 48% to 72%); absolute risk reductions were 2.7% per year for primary prevention and 8.4% per year for secondary prevention. Major extracranial bleeding was increased by warfarin therapy (absolute risk increase, 0.3% per year). Aspirin (six trials, 3119 participants) reduced stroke by 22% (CI, 2% to 38%); absolute risk reductions were 1.5% per year for primary prevention and 2.5% per year for secondary prevention. Adjusted-dose warfarin (five trials, 2837 participants) was more efficacious than aspirin (relative risk reduction, 36% [CI, 14% to 52%]). Other randomized comparisons yielded inconclusive results.

CONCLUSIONS:

Adjusted-dose warfarin and aspirin reduce stroke in patients with atrial fibrillation, and warfarin is substantially more efficacious than aspirin. The benefit of antithrombotic therapy was not offset by the occurrence of major hemorrhage among participants in randomized trials. Judicious use of antithrombotic therapy, tailored according to the inherent risk for stroke, importantly reduces stroke in patients with atrial fibrillation.

Mostrar resumen

Revisión sistemática

No clasificado

Antithrombotic agents for preventing thrombosis after infrainguinal arterial bypass surgery

Año 2011
Revista Cochrane Database of Systematic Reviews
Enlaces DOI , PMC , Pubmed

Este artículo incluye 23 Estudios primarios 23 Estudios primarios (23 referencias)

Cargando información sobre las referencias
Mostrar resumen

BACKGROUND:

Peripheral arterial disease (PAD) is frequently treated by either an infrainguinal autologous (using the patient's own veins) or synthetic graft bypass. The rate of occlusion of the graft after one year is between 12% and 60%. To prevent occlusion, patients are treated with an antiplatelet or antithrombotic drug, or a combination of both. Little is known about which drug is optimal to prevent infrainguinal graft occlusion. This is an update of a Cochrane review first published in 2003.

OBJECTIVES:

To evaluate whether antithrombotic treatment improves graft patency, limb salvage and survival in patients with chronic PAD undergoing infrainguinal bypass surgery.

SEARCH METHODS:

The Cochrane Peripheral Vascular Diseases Group searched their Specialised Register (last searched August 2010) and the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2010, Issue 3).

SELECTION CRITERIA:

Randomised, controlled trials; two review authors independently assessed the methodological quality of each trial using a standardised checklist.

DATA COLLECTION AND ANALYSIS:

Data collected included patient details, inclusion and exclusion criteria, type of graft, antithrombotic therapy, outcomes, and side effects.

MAIN RESULTS:

A total of 14 trials were included in this review; 4970 patient results were analysed. Four trials evaluating vitamin K antagonists (VKA) versus no VKA suggested that oral anticoagulation may favour autologous venous, but not artificial, graft patency as well as limb salvage and survival. Two other studies comparing VKA with aspirin (ASA) or aspirin and dipyridamole provided evidence to support a positive effect of VKA on the patency of venous but not artificial grafts. Three trials comparing low molecular weight heparin (LMWH) to unfractionated heparin (UFH) failed to demonstrate a significant difference on patency. One trial comparing LMWH with placebo found no significant improvement in graft patency over the first postoperative year in a population receiving aspirin. One trial showed an advantage for LMWH versus aspirin and dipyridamol at one year for patients undergoing limb salvage procedures. Perioperative administration of ancrod showed no greater benefit when compared to unfractionated heparin. Dextran 70 showed similar graft patency rates to LMWH but a significantly higher proportion of patients developed heart failure with dextran.

AUTHORS' CONCLUSIONS:

Patients undergoing infrainguinal venous graft are more likely to benefit from treatment with VKA than platelet inhibitors. Patients receiving an artificial graft benefit from platelet inhibitors (aspirin). However, the evidence is not conclusive. Randomised controlled trials with larger patient numbers are needed in the future to compare antithrombotic therapies with either placebo or antiplatelet therapies.

Mostrar resumen

Síntesis amplia

No clasificado

Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Año 2012
Revista Chest
Enlaces DOI , PMC , Pubmed

Este artículo incluye 75 Estudios primarios Estudios primarios (75 referencias) 10 Revisiones sistemáticas Revisiones sistemáticas (10 referencias)

Cargando información sobre las referencias
Mostrar resumen

BACKGROUND:

This article addresses the treatment of VTE disease.

METHODS:

We generated strong (Grade 1) and weak (Grade 2) recommendations based on high-quality (Grade A), moderate-quality (Grade B), and low-quality (Grade C) evidence.

RESULTS:

For acute DVT or pulmonary embolism (PE), we recommend initial parenteral anticoagulant therapy (Grade 1B) or anticoagulation with rivaroxaban. We suggest low-molecular-weight heparin (LMWH) or fondaparinux over IV unfractionated heparin (Grade 2C) or subcutaneous unfractionated heparin (Grade 2B). We suggest thrombolytic therapy for PE with hypotension (Grade 2C). For proximal DVT or PE, we recommend treatment of 3 months over shorter periods (Grade 1B). For a first proximal DVT or PE that is provoked by surgery or by a nonsurgical transient risk factor, we recommend 3 months of therapy (Grade 1B; Grade 2B if provoked by a nonsurgical risk factor and low or moderate bleeding risk); that is unprovoked, we suggest extended therapy if bleeding risk is low or moderate (Grade 2B) and recommend 3 months of therapy if bleeding risk is high (Grade 1B); and that is associated with active cancer, we recommend extended therapy (Grade 1B; Grade 2B if high bleeding risk) and suggest LMWH over vitamin K antagonists (Grade 2B). We suggest vitamin K antagonists or LMWH over dabigatran or rivaroxaban (Grade 2B). We suggest compression stockings to prevent the postthrombotic syndrome (Grade 2B). For extensive superficial vein thrombosis, we suggest prophylactic-dose fondaparinux or LMWH over no anticoagulation (Grade 2B), and suggest fondaparinux over LMWH (Grade 2C).

CONCLUSION:

Strong recommendations apply to most patients, whereas weak recommendations are sensitive to differences among patients, including their preferences.

Mostrar resumen

Revisión sistemática

No clasificado

Revisión sistemática de los ensayos clínicos sobre terapia antitrombótica con inhibidores del factor XI

Traducción oficial
Año 2024
Revista Rev. clín. esp. (Ed. impr.)
Enlaces Virtual Health Library , DOI

Sin referencias

Cargando información sobre las referencias
Mostrar resumen

Antecedentes y objetivo La información proveniente de los ensayos clínicos fase 2 sugiere que los inhibidores del factor XI podrían mostrar un perfil de eficacia/seguridad más favorable que las terapias antitrombóticas actuales. El objetivo de esta revisión sistemática es analizar la evidencia disponible derivada de esos estudios. Métodos Se realizó una búsqueda bibliográfica en las bases de datos PubMed, Cochrane Library, Scopus y EMBASE, y en las plataformas de registro de ensayos clínicos Clinical Trials y Cochrane Central Register of Controlled Trials. Los resultados se publicaron según la declaración PRISMA. Resultados Se identificaron un total de 18 ensayos clínicos concluidos o en curso abordando múltiples escenarios, incluyendo fibrilación auricular, ictus, infarto de miocardio y tromboembolismo venoso. Se analizó la evidencia procedente de 8 estudios con resultados disponibles. En general, los estudios fase 2 con inhibidores del factor XI mostraron un perfil adecuado de eficacia y seguridad. El balance beneficio/riesgo fue más favorable en términos de reducción de tromboembolismo venoso en pacientes sometidos a artroplastia total de rodilla. Para esta indicación, los inhibidores del factor XI mostraron una reducción global del 50% en la tasa de complicaciones trombóticas y del 60% en la tasa de hemorragias comparado con enoxaparina. En los estudios de pacientes con fibrilación auricular, ictus e infarto de miocardio se observaron resultados más modestos. Conclusión Los inhibidores del Factor XI abren nuevas perspectivas en el tratamiento y la profilaxis antitrombótica. Los estudios fase 3 en curso permitirán definir los fármacos e indicaciones más idóneas. (AU)

Mostrar resumen

Revisión sistemática

No clasificado

Antithrombotic Treatment for Acute Extracranial Carotid Artery Dissections: A Meta-Analysis.

Año 2015
Revista European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery
Enlaces DOI , Pubmed
Cargando información sobre las referencias
Mostrar resumen

INTRODUCTION:

Carotid artery dissection is a leading cause of stroke in younger patients, with an associated prevalence of 2.6-3.0 per 100,000 population. This meta-analysis aims to determine whether in patients managed medically, treatment with anticoagulants or antiplatelet agents was associated with a better outcome with respect to mortality, ischaemic stroke, and major bleeding episodes.

PATIENTS AND METHODS:

A comprehensive search strategy was employed of the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (January 1966 to March 2015), and EMBASE (January 1980 to March 2015) databases. Primary outcomes were death (all causes) or disability. Secondary outcomes were ischaemic stroke, symptomatic intracranial haemorrhage, and major extracranial haemorrhage during the reported follow-up period.

RESULTS:

No completed randomized trials were found. Comparing antiplatelets with anticoagulants across 38 studies (1,398 patients), there were no significant differences in the odds of death (effects size, ES, -0.007, p = .871), nor in the death and disability comparison or across any secondary outcomes.

CONCLUSION:

There were no randomised trials comparing either anticoagulants or antiplatelets with control, thus there is no level 1 evidence to support their routine use for the treatment of carotid artery dissection. Also, there were no randomised trials that directly compared anticoagulants with antiplatelet drugs, and the reported non-randomised studies did not show any evidence of a significant difference between the two.

Mostrar resumen

Síntesis amplia

No clasificado

VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Año 2012
Revista Chest
Enlaces DOI , PMC , Pubmed

Este artículo incluye 22 Revisiones sistemáticas Revisiones sistemáticas (22 referencias) 66 Estudios primarios Estudios primarios (66 referencias)

Cargando información sobre las referencias
Mostrar resumen

BACKGROUND:

The use of anticoagulant therapy during pregnancy is challenging because of the potential for both fetal and maternal complications. This guideline focuses on the management of VTE and thrombophilia as well as the use of antithrombotic agents during pregnancy.

METHODS:

The methods of this guideline follow the Methodology for the Development of Antithrombotic Therapy and Prevention of Thrombosis Guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines in this supplement.

RESULTS:

We recommend low-molecular-weight heparin for the prevention and treatment of VTE in pregnant women instead of unfractionated heparin (Grade 1B). For pregnant women with acute VTE, we suggest that anticoagulants be continued for at least 6 weeks postpartum (for a minimum duration of therapy of 3 months) compared with shorter durations of treatment (Grade 2C). For women who fulfill the laboratory criteria for antiphospholipid antibody (APLA) syndrome and meet the clinical APLA criteria based on a history of three or more pregnancy losses, we recommend antepartum administration of prophylactic or intermediate-dose unfractionated heparin or prophylactic low-molecular-weight heparin combined with low-dose aspirin (75-100 mg/d) over no treatment (Grade 1B). For women with inherited thrombophilia and a history of pregnancy complications, we suggest not to use antithrombotic prophylaxis (Grade 2C). For women with two or more miscarriages but without APLA or thrombophilia, we recommend against antithrombotic prophylaxis (Grade 1B).

CONCLUSIONS:

Most recommendations in this guideline are based on observational studies and extrapolation from other populations. There is an urgent need for appropriately designed studies in this population.

Mostrar resumen

Revisión sistemática

No clasificado

Long-term antithrombotic treatment in intracranial hemorrhage survivors with atrial fibrillation.

Año 2017
Revista Neurology
Enlaces DOI , PMC , Pubmed

Sin referencias

Cargando información sobre las referencias
Mostrar resumen

OBJECTIVE:

To perform a systematic review and meta-analysis of studies reporting recurrent intracranial hemorrhage (ICH) and ischemic stroke (IS) in ICH survivors with atrial fibrillation (AF) during long-term follow-up.

METHODS:

A comprehensive literature search including MEDLINE, EMBASE, Cochrane library, clinical trials registry was performed following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. We considered studies capturing outcome events (ICH recurrence and IS) for ≥3 months and treatment exposure to vitamin K antagonists (VKAs), antiplatelet agents (APAs), or no antithrombotic medication (no-ATM). Corresponding authors provided aggregate data for IS and ICH recurrence rate between 6 weeks after the event and 1 year of follow-up for each treatment exposure. Meta-analyses of pooled rate ratios (RRs) were conducted with the inverse variance method.

RESULTS:

Seventeen articles met inclusion criteria. Seven observational studies enrolling 2,452 patients were included in the meta-analysis. Pooled RR estimates for IS were lower for VKAs compared to APAs (RR = 0.45, 95% confidence interval [CI] 0.27–0.74, <i>p</i> = 0.002) and no-ATM (RR = 0.47, 95% CI 0.29–0.77, <i>p</i> = 0.002). Pooled RR estimates for ICH recurrence were not significantly increased across treatment groups (VKA vs

APA:

RR = 1.34, 95% CI 0.79–2.30, <i>p</i> = 0.28; VKA vs no

-ATM:

RR = 0.93, 95% CI 0.45–1.90, <i>p</i> = 0.84).

CONCLUSIONS:

In observational studies, anticoagulation with VKA is associated with a lower rate of IS than APA or no-ATM without increasing ICH recurrence significantly. A randomized controlled trial is needed to determine the net clinical benefit of anticoagulation in ICH survivors with AF. (PsycInfo Database Record (c) 2023 APA, all rights reserved)

Mostrar resumen

Revisión sistemática

No clasificado

Antithrombotics during fecal occult blood testing: a meta-analysis and systematic review

Año 2013
Revista Journal of Gastroenterology
Enlaces

Este artículo está incluido en 1 Resumen estructurado de revisiones sistemáticas 8 Resúmenes estructurados de revisiones sistemáticas (1 referencia)

Este artículo incluye 8 Estudios primarios 8 Estudios primarios (8 referencias)

Cargando información sobre las referencias
Mostrar resumen

BACKGROUND:

Fecal occult blood testing (FOBT) is commonly utilized as a screening modality for colon cancer. However, the effect of concurrent use of antithrombotics, including anticoagulation agents (warfarin, enoxaparin) and antiplatelet agents (aspirin, clopidogrel, NSAIDs, COX-2 inhibitors), on the yield of FOBT has not been well established. Therefore, a meta-analysis was performed to evaluate the effect of antithrombotics on the yield of FOBT.

METHODS:

Multiple databases were searched (July 2012). Studies examining the use of antithrombotics (aspirin, clopidogrel, NSAIDs, COX-2 inhibitors, warfarin, enoxaparin) versus no antithrombotics in patients with positive FOBT were included. Meta-analysis for the effect of antithrombotics or no antithrombotics for FOBT was performed by calculating pooled estimates of colonoscopy findings and detection of neoplasia, any adenoma, advanced adenoma, or colon cancer by odds ratio (OR) with fixed and random effects model. RevMan 5.1 was utilized for statistical analysis.

RESULTS:

Eight studies (N=2,800) met the inclusion criteria. No statistically significant differences were noted between FOBT with or without antithrombotics for colon cancer (OR 0.87; 95% CI.: 0.69-1.11, p=0.26), advanced adenoma (OR 0.92; 95% CI.: 0.62-1.37, p=0.70), colonoscopy findings (OR 0.76; 95% CI.: 0.42-1.37, p=0.37), neoplasia (OR 0.87; 95% CI.: 0.65-1.18, p=0.38), or any adenoma (OR 0.89; 95% CI.: 0.67-1.20, p=0.45).

CONCLUSION:

Among patients with positive FOBT, findings on colonoscopy do not appear to be affected by whether or not patients are taking antithrombotics.

Mostrar resumen

Revisión sistemática

No clasificado

Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls.

Año 1999
Revista Archives of internal medicine
Enlaces DOI , Pubmed

Sin referencias

Cargando información sobre las referencias
Mostrar resumen

OBJECTIVE:

To determine whether the risk of falling (with a possible increased chance of subdural hematoma) should influence the choice of antithrombotic therapy in elderly patients with atrial fibrillation.

DESIGN:

A Markov decision analytic model was used to determine the preferred treatment strategy (no antithrombotic therapy, long-term aspirin use, or long-term warfarin use) for patients with atrial fibrillation who are 65 years of age and older, are at risk for falling, and have no other contraindications to antithrombotic therapy. Input data were obtained by systematic review of MEDLINE. Outcomes were expressed as quality-adjusted life-years.

RESULTS:

For patients with average risks of stroke and falling, warfarin therapy was associated with 12.90 quality-adjusted life-years per patient; aspirin therapy, 11.17 quality-adjusted life-years; and no antithrombotic therapy, 10.15 quality-adjusted life-years. Sensitivity analysis demonstrated that, regardless of the patients' age or baseline risk of stroke, the risk of falling was not an important factor in determining their optimal antithrombotic therapy.

CONCLUSIONS:

For elderly patients with atrial fibrillation, the choice of optimal therapy to prevent stroke depends on many clinical factors, especially their baseline risk of stroke. However, patients' propensity to fall is not an important factor in this decision.

Mostrar resumen